Michael H. Gold, MD, is the founder and medical director of Gold Skin Care Center, Advanced Aesthetics Medical Spa, The Laser & Rejuvenation Center.

Today, scar management is a critical yet often underappreciated element of dermatologic care, especially for individuals with skin of color, where differences in pigmentation and healing responses can raise the risk of hypertrophic scarring.

The value of tailored, evidence-based approaches to address both clinical outcomes and cosmetic concerns in such populations has been expressed more and more in recent years. In light of this , the topic was highlighted during the 

2026 American Academy of Dermatology (AAD) Annual Meeting

 in Denver in a session titled ‘The Art of Healing- Scar Management Strategies Tailored to Ethnic Skin.’

 editorial team spoke with Michael H. Gold, MD, the founder and medical director of Gold Skin Care Center, Advanced Aesthetics Medical Spa, & The Laser & Rejuvenation Center, who spoke about a variety of key insights from his session on scar management in patients with skin of color.

In the following Q&A interview, Gold highlights notable takeaways from his session on scar management at AAD 2026:

You presented on combining surgery and radiotherapy during the ‘The Art of Healing- Scar Management Strategies Tailored to Ethnic Skin’ session at AAD. Why did you feel this was a necessary topic to highlight for dermatology clinicians?

Scars are a big deal in my world. I've been working on, researching, and treating scars my entire career. I'm a medical doctor. I'm not a cosmetic doc, but they do biopsies, so they're creating a scar. They're cosmetic in some way because they want that scar to look good. But I deal with really bad scars. Many years ago, I wrote the first dermatology paper on silicone gel as a method, not a total treatment, but as a method to improve the appearance of scars. And we know with silicone, whether it's gel or sheets, we can flatten scars over time. Many times, they take the colors back to normal. And that's a great thing, right?

It's not the end-all be-all, but if you looked at the marketplace, there was one product that was around 30-some odd years ago. We have many now. So, as an adjunct to almost everything I do, I recommend that patients take home silicone and use it as one of the gels or sheets on their scars. When you take energy-based devices, we have lots of different things that we've gone through over the years to improve things. So we have fractional lasers, non-ablative fractional lasers. Ablative fractional lasers, microneedling with radio frequency, and other things like pulsed dye lasers and other vascular lasers. We use these to improve the appearance of scars and reduce their appearance.

 What else can you tell us about your experience in this area and the other highlights from your talk?

I spent a lot of my time over the last 20 years working with physicians all over the world, but especially in China, where we've really honed in on the techniques and how we can combine things together. Whether it's a fractional CO2 or a vascular laser. We can make most scars and most contracted scars…we can make their hands move.

You don't always need surgery for that. Laser surgery actually works for that. If you know how to do it, you have the right devices. The devices have gotten much better, and so we love using energy-based devices in scar therapy. I think the hardest thing is that somebody has a burn injury, and I'm going to tell them, ‘I'm going to take a laser, which is also a burn injury, to that scar.’ You have to explain it. You have to talk to the patient about why you're doing it, what it does, and how it works. But they work really well. Then on the radiation side, superficial radiation therapy, or just radiation therapy, was actually started by dermatologists, and we gave it away to the radiation oncology people.

Now we're bringing it back into dermatology. So in my office, and in many offices, we have radiation therapy. In our clinics, they have FDA approval for non-melanoma skin cancers and for keloids. The way keloids work, and if you cut a keloid, the recurrence rate, just cutting alone, can vary between 50 and 80% that's a lot if you do radiation therapy following the excision, and the way we do it is three consecutive days. We have published papers with others, and after one year, the recurrence rate is about 10% or less. That's pretty magical. So it's not for everybody, because we have to have the device right, and we have to make sure we're delivering the right amount of radiation.

This is superficial radiation therapy, and it's safe and effective. So, if I can take a 50 to 80% recurrence rate to 10. I'm really comfortable, right? And my patients are thrilled. So I love using radiation therapy. I do use it in conjunction with other things, like silicone gel and other things that I use, but my patients are really happy.

The quotes contained in this Q&A summary were edited for clarity.

Gold reports relationships with multiple companies, including roles as a consultant (honoraria) for Acclaro Medical, Aesthetic Management Partners, Aesthetics Biomedical, Alastin Skincare, Inc., Allergan, Inc., Benev, Galderma, Hugel, InMode, La Mer, Mindera, MTF Biologics, Nutrafol, Pierre Fabre, Prescriber’s Choice, Revision Skincare, Rohrer Aesthetics, Sciton Inc., Sensus Healthcare, Sente Labs, SkinBetter Science, SkinCeuticals LLC, SkinMedica, Inc., Sofwave, Stratapharma, and VIOL. He has served as a speaker (honoraria) for Alma Lasers, Cutera, Inc., EndyMed Medical Inc. USA, Lumenis, Merz Pharmaceuticals, LLC, and Venus Concept. He is an investigator (grants/research funding) for Bausch Health, Leo Pharma Inc., Revance Therapeutics, Inc., Revision Skincare, and SkinBetter Science. He also reports stockholder status with Aerolase and stock options with Venus Concept.

Gold M, et al. F081 The Art of Healing- Scar Management Strategies Tailored to Ethnic Skin. Session presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.


Articles

Scar management in skin of color warrants tailored, evidence-based strategies given heightened risks of hypertrophic scarring and pigmentary sequelae. Multimodal care integrates foundational topical silicone (gel or sheets) with energy-based interventions such as fractional non-ablative/ablative lasers, RF microneedling, and vascular lasers to improve scar thickness, color, and function, including contractures. For keloids, superficial radiation therapy after excision—delivered over three consecutive days—can markedly reduce recurrence versus surgery alone, contingent on appropriate devices and dosing.

In this Q&A interview at AAD 2026, Gold highlights various tips and strategies for healing scars among patients with skin of color.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Scar Management Strategies Tailored to Patients of Color, With Michael H. Gold, MD

Andrew Yockey, PhD, assistant professor at the University of Mississippi.

 Adolescent Depressive Episodes Declined From 2021- 2024, With Andrew Yockey, PHD

New national survey data reveal a nearly 40% decline in adolescent 

following the pandemic, but experts caution that improvements should not overshadow persistent disparities, diagnostic challenges, and gaps in care.

 investigator Andrew Yockey, PhD, assistant professor at the University of Mississippi, discussed findings from a recent analysis of the 2021–2024 National Survey on Drug Use and Health (NSDUH), which found a notable decline in past-year major depressive episodes (MDE) among 43,828 US adolescents aged 12 to 17 years. Prevalence decreased from 20.5% in 2021 to 14.8% in 2024, representing a 38.5% relative reduction.

“I think there is a partial recovery,” Yockey said. “During COVID, I think things just got hammered, and things just got very bad in terms of mental health, and we don’t know enough about the recovery time. Seeing that decline really helps.”

Yockey said other factors could contribute to the decline in depressive episodes, including better screening, an uptick in telehealth services, and reduced stigma of mental health care through national campaigns.

“Things are getting better, but let's not mitigate the issue here that 1 in 5 adolescents have mental health conditions,” he said.

The study confirmed several well-established risk patterns. Girls had > 3-fold greater odds of a major depressive episode compared with boys, and older adolescents were at increased risk. Racial and ethnic differences were also observed, with multiracial adolescents experiencing greater odds of depression. Alcohol and marijuana use were associated with increased odds of major depressive episodes, reinforcing the importance of integrated behavioral health approaches that address both mood symptoms and substance use.

Although girls continue to have greater rates of depression, boys have higher suicide completion rates, illustrating the importance of nuanced assessment. Yockey encouraged clinicians to recognize that adolescent depression may present beyond sadness, including irritability, substance use, emotional withdrawal, and loss of direction.

Yockey emphasized the need for broader and more nuanced research to determine whether improvements are sustained. Priorities include examining neurobiological and cognitive factors, as well as emotional processes such as rumination and emotional suppression. Intersectionality was also identified as an underexplored area, as adolescents with overlapping marginalized identities may experience unique stressors affecting mental health that are not captured in current screening approaches.

Yockey also highlighted the need to modernize screening tools, noting that traditional instruments may not fully capture irritability, cultural distress, or evolving symptom presentations among adolescents. He stressed the importance of connecting adolescents to treatment pathways, including therapy, medication when appropriate, and community-based resources.

“One of the things that I've always envisioned is having youth support groups in schools,” Yockey said. “We know from our research that if youth are involved with their parents or they're involved in a social activity, they’re less likely to report depression and substance use, so getting better ways to engage youth is critical.”

Andrew Yockey R, Apu A, Grigsby T, Bleasdale J, Mattingly D, Hoopsick R. Decreasing prevalence in youth depressive episodes: Evidence from the 2021-2024 national survey on drug use and health. J Psychiatr Res. 2026 Mar 25;198:188-191. 

Videos

Survey data show a nearly 40% drop in adolescent depressive episodes post-pandemic, though clinicians should remain vigilant for disparities and unmet care needs, Yockey says.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Adolescent Depressive Episodes Declined From 2021- 2024, With Andrew Yockey, PhD

Nancy Reau, MD, is Professor of Internal Medicine, Richard B. Capps Chair of Hepatology, Associate Director of Solid Organ Transplantation, and Section Chief of Hepatology at Rush University Medical Center.

Kimberly Brown, MD, is division chief of gastroenterology and hepatology and the Associate Medical Director of the Henry Ford Hospital Transplant Institute at Henry Ford Hospital. She is also a Professor of Medicine at Wayne State University

Saul Karpen, MD, PhD, is is the inaugural chief scientific officer for the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University, Richmond, Va., where he is a professor of internal medicine and adjunct professor in pediatric medicine at the VCU School of Medicine. He holds the Phillip B. Hylemon Endowed Chair of Medicine and Microbiology and is a pediatric hepatologist at the VCU Children’s Hospital of Richmond. He is also the president of AASLD.

Robert Gish, MD, is the Medical Director of the Hepatitis B Foundation in Doylestown, Pennsylvania. He is an Adjunct Professor of Medicine at the University of Nevada School of Medicine in Las Vegas. He serves as an Adjunct Professor of Pharmacy at Skaggs School of Pharmacy and Pharmaceutical Sciences at UCSD, a Clinical Professor of Medicine at Loma Linda University. In addition, he is the Medical Director of the American Pacific Health Foundation.

Liver Lineup: Navigating Genetic Testing in Cholestatic Liver Disease

Genetic testing is rapidly reshaping the diagnostic and therapeutic landscape of cholestatic liver disease, but for many practicing hepatologists, its clinical application remains uncertain. In the latest episode of Liver Lineup, hosts Nancy Reau, MD, and Kimberly Brown, MD, are joined by Saul Karpen, MD, PhD, inaugural chief scientific officer for the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University and president of AASLD, and Robert Gish, MD, medical director of the Hepatitis B Foundation and the American Pacific Health Foundation, to unpack the evolving role of genetic testing in cholestatic disorders and provide practical guidance for integrating these tools into routine care.

Karpen, a pediatric hepatologist with decades of experience in cholestasis, outlined the historical arc of genetic testing in liver disease. Early approaches were laborious and limited, often requiring single-gene sequencing following invasive biopsies and yielding inconclusive results. However, advances over the past decade, particularly the advent of exome-based sequencing panels, have enabled clinicians to assess dozens of relevant genes simultaneously.

This shift has transformed genetic testing from a niche diagnostic tool into a foundational component of pediatric hepatology. Today, Karpen emphasized, such panels are “part of the fabric” of clinical evaluation in children with unexplained cholestasis.

For adult hepatologists, adoption has been slower, in part due to differences in clinical expectations. While pediatric providers may accept a modest diagnostic yield, adult clinicians often seek higher certainty before ordering specialized tests. Yet, as Gish highlighted, this mindset may need to evolve.

Drawing on his own experience ordering genetic panels, he noted that the majority of patients demonstrate ≥ 1 genetic variants, findings that can meaningfully inform diagnosis, risk stratification, and management.

Both experts emphasized that genetic testing should not be reserved solely for rare or refractory cases. Instead, it should be considered in a range of clinical scenarios, including unexplained cholestatic or mixed-pattern liver enzyme abnormalities, antimitochondrial antibody (AMA)-negative primary biliary cholangitis, atypical drug-induced liver injury, intrahepatic cholestasis of pregnancy, and even lean metabolic dysfunction-associated steatotic liver disease (MASLD). Importantly, these tests can uncover underlying genetic susceptibilities that may not have been clinically apparent.

A key challenge, however, lies in interpretation. Results frequently include variants of uncertain significance (VUS), which can create confusion and anxiety for both clinicians and patients. Karpen and Gish acknowledged this limitation but stressed that uncertainty is not unique to genetics—hepatologists routinely navigate ambiguous findings in imaging, histology, and laboratory testing. The critical step is correlating genetic results with the clinical phenotype, using them as one piece of a broader diagnostic puzzle.

Among the most clinically relevant genes discussed were 

, both of which play central roles in bile formation and transport. Variants in these genes can predispose patients to a spectrum of cholestatic conditions, sometimes manifesting only under physiologic stressors such as pregnancy, infection, or medication exposure. Notably, even heterozygous variants, traditionally considered benign, may contribute to disease in certain contexts, underscoring the concept of “synergistic heterozygosity.”

The conversation also highlighted the growing therapeutic implications of genetic insights. Identification of specific variants may guide treatment decisions, including the use of ursodeoxycholic acid or newer agents such as ileal bile acid transporter (IBAT) inhibitors. In some cases, genetic findings can explain treatment resistance or predict response, enabling more personalized care.

Despite these advances, both speakers agreed that collaboration remains essential. While geneticists can provide valuable support, particularly for complex cases requiring whole-exome sequencing, hepatologists must develop a working knowledge of key genes and interpretation principles. As Karpen noted, the field is still evolving, and variant classifications may change over time as new data emerge.

Editors’ note: Relevant disclosures for 

 include AbbVie, Gilead, Salix, Arbutus, and VIR. Relevant disclosures for 

 include Mallinckrodt Pharmaceuticals, Gilead, Salix, Intercept, Ipsen, and Madrigal. Relevant disclosures for 

 include Mirum and Ipsen. Relevant disclosures for 

 include Abbott, AbbVie, Aligos, Altimmune, Arrowhead, AstraZeneca, Corcept, Genentech, Gilead Sciences, GSK, Intercept, Janssen, Merck, Perspectum, Pfizer, and others.

Hasegawa S, Yoneda M, Kurita Y, et al. Cholestatic Liver Disease: Current Treatment Strategies and New Therapeutic Agents. 

. 2021;81(10):1181-1192. doi:10.1007/s40265-021-01545-7

Brooks A. FDA Approves Linerixibat (Lynavoy) As First Treatment for Cholestatic Pruritus in PBC. HCPLive. March 19, 2026. Accessed April 7, 2026. 

https://www.hcplive.com/view/fda-approves-linerixibat-lynavoy-as-first-treatment-for-cholestatic-pruritus-in-pbc

Podcasts

Experts discuss when to use genetic testing in cholestatic disease, how to interpret results, and its growing role in diagnosis and management.

Liver Lineup: Updates & Unfiltered Insights

Introducing Liver Lineup: Updates & Unfiltered Insights — an exciting new podcast delivering timely, candid perspectives on the most pressing topics in the fast-moving world of hepatology. Created by Nancy Reau, MD, and Kimberly Brown, MD, and hosted by HCPLive, this series dives into the cutting edge of liver disease research, clinical care, and real-world practice.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Hepatology

Cholangitis

cholangitis page, resources on the topics of medical news and expert insight into cholangitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on research, treatment, and drug development in PBC, PSC, and more!

Acne remains one of the most prevalent and clinically consequential conditions in all of dermatology, representing the most common skin disorder seen in clinical practice and increasing in prevalence since 1990.

Against this backdrop, the condition continues to generate significant interest at notable dermatology conferences; the 

 editorial team spoke with Michael H. Gold, MD, the founder and medical director of Gold Skin Care Center, Advanced Aesthetics Medical Spa, & The Laser & Rejuvenation Center, who discussed his session at AAD: ‘Acne Boot Camp.’

The following Q&A interview highlights the team’s questions and Gold’s responses regarding takeaways from his session on acne treatments at AAD:

Following your session here at AAD titled ‘Acne Boot Camp’ session, we would like to know why you felt this was an important topic to present about to clinicians in today’s acne treatment landscape?

 So in the acne world, we have lots of medicines. They've been around for a long time, some new ones. We have great ways to treat our patients, but they take time. What I've always said over the years is that my patients want to be better yesterday. One of the ways I can add to this, it's not always by itself, is when you add in energy-based devices. We can make people better faster. It's always been my premise, and my way I want to approach things with my patients when it's appropriate.

Energy-based is in my world, and in most worlds, is strictly a cosmetic type of procedure, so it's cash based, and that changes the game in some ways. But if you keep the acne costs with the devices reasonable, and you deliver the results, then it becomes a successful part of the treatments. So that's why I do it, and I've been doing it for 25 years.

 We know in your portion of the session on acne treatment that you talk about lasers and light sources for acne. So what are some of the lasers and light sources you touch on?

We actually break it into two different categories. The [cutibacterium acnes] bacteria is important. It actually has porphyrin in it, and we can use the absorption spectrum of porphyrin to target the porphyrin. If we destroy the porphyrin in the bacteria, we destroy the bacteria selectively, and the acne gets better. So there's a variety of devices that work for that. That's one way to do it.

Then in the past few years, we've actually had selective sebaceous gland destruction with the device that devices that are at 1726 nanometers that actually targets the sebaceous gland. If you destroy the sebaceous gland, the acne gets better. Is it total control and is it total clearance? Not every time, but the results are pretty spectacular. So for both ways to do it, we get great results.

What do you feel are the biggest misconceptions about acne, if there are any currently?

 I don't know if there's a lot of misconceptions. I think that one of the things that we don't do well at is to actually think about and work with with and through the psychosocial aspects of acne when we see patients. That's my biggest thing. Now, I had really bad acne as a kid, so I understand it a little bit more, not that I had any psychosocial issues, but I see it. And we see it, so we have to be able to deal with it.

We're all busy, so when we're busy, that becomes back burner thing, right? But if you actually start talking to the patients and parents and all, you get a sense of how aggressive you sometimes need to be. That's when I'd like to start the conversations about energy based devices with my patients.

 Is there an earlier age at which you feel like that's important to begin using these treatments?

We treat people with acne with devices in their teens, so all the way up. So I don't and what I say to people in our community, you have to be very careful, because if you hurt a child, they're done. You're done with that patient. So we have to make sure that we do these things so that the pain part of this is minimal. There's always some discomfort when you use a device, but we have ways to make it virtually painless in most cases.

hat do you feel like the horizon looks like as far as acne treatments are concerned? Are you positive about the landscape currently?

think when we look at the future, we need more medicines, we need better medicines. We need targeted medicines, and I think we've gotten some over the years. I think that if you look at the dermatology community, acne is now on the back burner for many compared to psoriasis, atopic dermatitis, and all the other things that we're dealing with like HS, vitiligo, alopecia areata, and that's okay. But acne is a big part of every dermatologist practice, and it just is something that we have to take seriously, and we have to make sure our patients are getting better.

Zhu Z, Zhong X, Luo Z, Liu M, Zhang H, Zheng H, Li J. Global, regional and national burdens of acne vulgaris in adolescents and young adults aged 10-24 years from 1990 to 2021: a trend analysis. Br J Dermatol. 2025 Jan 24;192(2):228-237. doi: 10.1093/bjd/ljae352. PMID: 39271178.

Gold M, et al. F019 Acne Boot Camp. Session presented at: 2026 American Academy of Dermatology Annual Meeting; March 27–31, 2026; Denver, CO.

This Q&A interview with Gold at AAD 2026 highlights notable takeaways from his portion of the session titled 'Acne Boot Camp.'

Acne

The HCPLive acne page is a resource for medical news and expert insights on dermatological disease. This page features expert-led coverage, articles, videos, and research on the therapies and development of treatments for chronic acne, and more.

Strategies and Technologies for Acne Treatment in 2026, With Michael H. Gold, MD

John Cijan He, MD, PhD, is a Professor of Medicine and Pharmacological Sciences and Chief of the Division of Nephrology at the Icahn School of Medicine at Mount Sinai.

Emerging Targets in Podocyte Injury Signal Shift in Glomerular Disease Treatment, With John Cijiang He, MD, PhD

An evolving understanding of podocyte injury in glomerular disease is being driven by advances in genetics, targeted therapeutics, and biomarker development, signaling a shift beyond traditional immunosuppression.

Recently, John Cijiang He, MD, PhD, Professor of Medicine and Pharmacological Sciences and Chief of the Division of Nephrology at the Icahn School of Medicine at Mount Sinai, spoke with 

he discussed the growing recognition of podocyte injury as a central mechanism in 

focal segmental glomerulosclerosis (FSGS)

Podocytes are highly specialized visceral epithelial cells that, along with glomerular endothelial cells and the glomerular basement membrane, form the glomerular filtration barrier. This structure allows waste products to pass while preventing the leakage of plasma proteins such as albumin. Podocytes are characterized by interdigitating foot processes connected by slit diaphragms, which serve as a critical final filtration barrier.

A notable feature of podocytes is that they are terminally differentiated, meaning they have limited capacity to proliferate. As a result, podocyte loss is difficult to recover. Injury caused by infection, genetic defects, or immune-mediated damage can lead to foot process effacement, disruption of the slit diaphragm, and proteinuria, currently the most widely used noninvasive biomarker of glomerular injury. Progressive podocyte damage contributes to chronic kidney disease (CKD) and eventual kidney failure.

Genetic mutations remain a key driver of podocyte injury, particularly in pediatric populations. In addition, APOL1 high-risk variants, most commonly identified in individuals of African ancestry, are strongly associated with increased risk of kidney disease. APOL1-mediated glomerular disease often presents similarly to FSGS and is thought to involve mechanisms including dysregulated ion channel activity that contribute to podocyte injury.

Proteinuria, while widely used in clinical practice, may reflect relatively advanced disease, with substantial podocyte injury already present at the time of detection. As a result, emerging therapeutic strategies are being explored, including early-stage gene-based approaches and interventions targeting downstream molecular pathways to restore podocyte function. These approaches align with a broader shift toward precision medicine in nephrology.

In APOL1-associated disease, early-phase clinical trials have demonstrated reductions in proteinuria with small molecule inhibitors targeting APOL1-mediated pathways. Ongoing phase 3 trials are further evaluating these therapies, which could represent the first targeted treatment for a genetically defined subgroup of glomerular disease.

Additional emerging targets include lipid toxicity and metabolic dysfunction. Dysregulated lipid uptake in podocytes can lead to lipotoxicity and cellular injury, prompting investigation into therapies that inhibit lipid accumulation. Furthermore, ion channel dysregulation, such as gain-of-function mutations, has been implicated in podocyte injury. Targeted inhibitors of these pathways are currently being evaluated in phase 2 clinical trials, with early data suggesting potential reductions in proteinuria.

Although these approaches remain investigational, they underscore a growing shift toward mechanism-based, podocyte-directed therapies in glomerular disease.

https://doi.org/10.12688/f1000research.7255.1

Hillenbrand A. Podocyte Injury Emerges as Central Driver of Progression in FSGS, Diabetic Kidney Disease. HCPLive. Published 2026. Accessed April 7, 2026. 

https://www.hcplive.com/view/podocyte-injury-emerges-as-central-driver-of-progression-in-fsgs-and-diabetic-kidney-disease

Zimmerman B, Dakin LA, Fortier A, et al. Small molecule APOL1 inhibitors as a precision medicine approach for APOL1-mediated kidney disease. 

https://doi.org/10.1038/s41467-024-55408-2

Luo Z, Chen Z, Hu J, Ding G. Interplay of lipid metabolism and inflammation in podocyte injury. 

https://doi.org/10.1016/j.metabol.2023.155718

Hu H, Liang W, Ding G. Podocyte Metabolic Reprogramming and Targeted Therapy. 

Journal of the American Society of Nephrology : JASN

An expert shares his perspective on emerging targets and precision strategies for podocyte injury in glomerular disease. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Focal Segmental Glomerulosclerosis

The HCPLive focal segmental glomerulosclerosis page is a resource for medical news and expert insights on FSGS. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in FSGS, and more. 

Strategic Alliance Partnership

Ann Marie Navar, MD, PhD, is an associate professor of cardiology at the University of Texas Southwestern Medical Center.

Navar discusses the phase 3 CORALreef AddOn trial, highlighting enlicitide’s superiority to ezetimibe, bempedoic acid, and a combination of both.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Dyslipidemia

CORALreef AddOn: Enlicitide Outperforms Standard Hypercholesterolemia Drugs, With Ann Marie Navar, MD, PhD

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

FDA approvals, new HAE guidance, epinephrine access shifts, and phase 3 peanut patch data defined major allergy developments across Q1 2026.


Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Food Allergy

Q1 2026 Recap: Allergy News and Updates

Jawad Butt, MD, PhD, is a research fellow in the department of cardiology at Copenhagen University Hospital and the University of Glasgow.

Butt discusses his secondary analysis of the FINEARTS-HF trial, which demonstrated consistent treatment efficacy in patients with and without a history of IHD.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Finerenone Efficacy in HF Unchanged by Ischemic Heart Disease, With Jawad Butt, MD, PhD

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Key hepatology updates from March 2026, including a first-in-class PBC therapy, viral hepatitis insights, and emerging research in MASLD and HCC.

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

6 Hepatology Headlines You Missed in March 2026

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

This summary of March 2026 highlights key news and developments in the dermatology news space.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

6 Dermatology Headlines You Missed in March 2026

Lingfeng Xue, PhD, an old age psychiatry and clinical research assistant at King’s College London.

Interview with Xue on UK Biobank data linking first-onset depression after age 50 to cognitive deficits and increased dementia risk.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

Dementia Risk Signals in Late-Onset Depression, With Lingfeng Xue, PhD 

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Jessica Castle, MD, joins the show to give a peek behind the curtain at Dexcom’s latest advancements in CGM technology.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 1 Diabetes

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

Diabetes Dialogue: The G7 15-Day System and CGM Innovations at Dexcom, With Jessica Castle, MD

Catch up on new IBD drug trial data, updated HE guidelines from the American College of Gastroenterology, and more.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Exocrine Pancreatic Insufficiency

The HCPLive Exocrine Pancreatic Insufficiency page is a comprehensive resource for clinical news and insights on exocrine pancreatic insufficiency. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

5 Gastroenterology Headlines You Missed in March 2026

Podocyte Injury Emerges as Central Driver of Progression in FSGS, Diabetic Kidney Disease

Rapid psychedelic therapies, accelerated TMS protocols, AI-driven care debates, and semaglutide’s link to reduced suicidality shaped psychiatry headlines in March 2026.

Latest News

Scar Management Strategies Tailored to Patients of Color, With Michael H. Gold, MD

Adolescent Depressive Episodes Declined From 2021- 2024, With Andrew Yockey, PhD

Liver Lineup: Navigating Genetic Testing in Cholestatic Liver Disease

Strategies and Technologies for Acne Treatment in 2026, With Michael H. Gold, MD

Emerging Targets in Podocyte Injury Signal Shift in Glomerular Disease Treatment, With John Cijiang He, MD, PhD